The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

case-study
From Licensing to Acquisition: End-to-End CMC Enablement for a Clinical-Stage Biotech
Read More

post
Post-Approval CMC Changes: Strategies for Compliant Growth
Read More

post
Early Regulatory Strategy for Biotech Startups
Read More

post
Using Non-Animal Toxicology? Start with the FDA Conversation
Read More
Let's move from science to success.
Let’s Talk